Cadmus Rich
Director/Board Member at Sustained Nano Systems LLC
Net worth: 51 520 $ as of 2024-03-30
Profile
Cadmus Collins Rich is currently a Director at Sustained Nano Systems LLC.
He was previously a Director at North Carolina Specialty Hospital LLC and Treasurer & Director at National Society to Prevent Blindness.
He served as VP-Medical Affairs & Clinical Development at Inotek Pharmaceuticals Corp.
from 2015 to 2017.
From 2017 to 2023, he was the Chief Medical Officer, Head-Research & Development at Aura Biosciences, Inc. Dr. Rich has an undergraduate degree from Case Western Reserve University, an MBA from Regis University, and a doctorate from UNC School of Medicine.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
AURA BIOSCIENCES INC
0.01% | 2023-03-30 | 6,563 ( 0.01% ) | 51 520 $ | 2024-03-30 |
Cadmus Rich active positions
Companies | Position | Start |
---|---|---|
Sustained Nano Systems LLC
Sustained Nano Systems LLC Miscellaneous Commercial ServicesCommercial Services Sustained Nano Systems LLC is a company that develops products for post-cataract surgery treatment. The company is based in Westhampton Beach, NY and was founded by Barry M. Libin, who has been the CEO since incorporation. The company's products include dex-sa, which delivers dexamethasone to the subconjunctival space to treat postoperative inflammation and pain, and lat-la, a single extraocular injectable administration of a six-month release prostaglandin analog for glaucoma treatment. The company also develops SNS ret-la, which prevents blood vessel growth for over a year in a standard rabbit model of corneal angiogenesis. | Director/Board Member | - |
Former positions of Cadmus Rich
Companies | Position | End |
---|---|---|
AURA BIOSCIENCES, INC. | Chief Tech/Sci/R&D Officer | 2023-10-15 |
Inotek Pharmaceuticals Corp.
Inotek Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Inotek Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. The company's product candidate includes Trabodenoson, an adenosine mimetic that has completed Phase II clinical trials for lowering IOP by restoring the eye's natural pressure control mechanism. It is also developing Trabodenoson plus Latanoprost, a prostaglandin analogue that has completed Phase II clinical trials for use in patients with inadequate responses to treatment with latanoprost; and Trabodenoson monotherapy for the treatment of optic nerve neuropathy. Inotek Pharmaceuticals was founded on July 7, 1999 by Csaba Szabo and Andrew L. Salzman and is headquartered in Lexington, MA. | Chief Tech/Sci/R&D Officer | 2017-08-31 |
North Carolina Specialty Hospital LLC | Director/Board Member | - |
National Society to Prevent Blindness
National Society to Prevent Blindness Miscellaneous Commercial ServicesCommercial Services National Society to Prevent Blindness operates as an eye health and safety organization. It offers services for amblyopia, AMD, cataract, central retinal vein occlusion, colour blindness, conjunctivitis, diabetic eye disease and macular enema, dry eye, floaters, glaucoma, refractive eye, retinal tears and detachments, retinitis pigments and strabismus. The company was founded in 1908 and is headquartered in Chicago, IL. | Director/Board Member | - |
Training of Cadmus Rich
Case Western Reserve University | Undergraduate Degree |
Regis University | Masters Business Admin |
UNC School of Medicine | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
AURA BIOSCIENCES, INC. | Health Technology |
Private companies | 4 |
---|---|
North Carolina Specialty Hospital LLC | |
Inotek Pharmaceuticals Corp.
Inotek Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Inotek Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. The company's product candidate includes Trabodenoson, an adenosine mimetic that has completed Phase II clinical trials for lowering IOP by restoring the eye's natural pressure control mechanism. It is also developing Trabodenoson plus Latanoprost, a prostaglandin analogue that has completed Phase II clinical trials for use in patients with inadequate responses to treatment with latanoprost; and Trabodenoson monotherapy for the treatment of optic nerve neuropathy. Inotek Pharmaceuticals was founded on July 7, 1999 by Csaba Szabo and Andrew L. Salzman and is headquartered in Lexington, MA. | Health Technology |
National Society to Prevent Blindness
National Society to Prevent Blindness Miscellaneous Commercial ServicesCommercial Services National Society to Prevent Blindness operates as an eye health and safety organization. It offers services for amblyopia, AMD, cataract, central retinal vein occlusion, colour blindness, conjunctivitis, diabetic eye disease and macular enema, dry eye, floaters, glaucoma, refractive eye, retinal tears and detachments, retinitis pigments and strabismus. The company was founded in 1908 and is headquartered in Chicago, IL. | Commercial Services |
Sustained Nano Systems LLC
Sustained Nano Systems LLC Miscellaneous Commercial ServicesCommercial Services Sustained Nano Systems LLC is a company that develops products for post-cataract surgery treatment. The company is based in Westhampton Beach, NY and was founded by Barry M. Libin, who has been the CEO since incorporation. The company's products include dex-sa, which delivers dexamethasone to the subconjunctival space to treat postoperative inflammation and pain, and lat-la, a single extraocular injectable administration of a six-month release prostaglandin analog for glaucoma treatment. The company also develops SNS ret-la, which prevents blood vessel growth for over a year in a standard rabbit model of corneal angiogenesis. | Commercial Services |
- Stock Market
- Insiders
- Cadmus Rich